



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Svendsen et al.

Application No.: 09/441,313

Group Art Unit: 1632

Filed: November 16, 1999

Examiner: To be assigned

For: α -amylase variants**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 96/23873;
2. WO 95/26397;
3. WO 95/10603;
4. WO 90/11352; and

5. WO 96/23874.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: February 2, 2000


Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Attorney Docket No.: 5709.200-U.S.

PATENT

GP 1632
#81
2/16/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of: Svendsen et al.

Serial No.: 09/441,313

Group Art Unit: 1632

Filed: November 16, 1999

Examiner: To be assigned

For: α -amylase variants

FEB 16 2000
TECH CENTER 1600/2000

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Transmittal of Information Disclosure Statement
2. Information Disclosure Statement
3. PTO-1449 Form
4. Copy of References


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks
Washington, DC 20231

on February 2, 2000.

Carol McFarlane
(name of person mailing paper)

Carol McFarlane
(signature of person mailing paper)



Attorney Docket No.: 5709.200-U.S.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Application No.: 09/441,313

Group Art Unit: 1632

Filed: November 16, 1999

Examiner: To be assigned

For: α -amylase variants

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS (37 C.F.R. 1.97(b))**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application. Therefore, no fee is due.

Respectfully submitted,

Date: February 2, 2000


Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123